JP2023516300A - 腫瘍浸潤リンパ球の活性化及び増殖のための方法 - Google Patents

腫瘍浸潤リンパ球の活性化及び増殖のための方法 Download PDF

Info

Publication number
JP2023516300A
JP2023516300A JP2022551637A JP2022551637A JP2023516300A JP 2023516300 A JP2023516300 A JP 2023516300A JP 2022551637 A JP2022551637 A JP 2022551637A JP 2022551637 A JP2022551637 A JP 2022551637A JP 2023516300 A JP2023516300 A JP 2023516300A
Authority
JP
Japan
Prior art keywords
tils
population
cytokine
culture medium
final concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022551637A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021173964A5 (https=
JP2023516300A5 (https=
Inventor
マイカ ベンソン，
ノア ジェイコブ トゥボ，
ニコラス ジョン コレッティ，
ロバート アンドリュー レモト，
グレゴリー ブイ． クリュコフ，
マイケル アール． シュラバック，
ショーン フィリップ リアリー アローカス，
Original Assignee
ケーエスキュー セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケーエスキュー セラピューティクス， インコーポレイテッド filed Critical ケーエスキュー セラピューティクス， インコーポレイテッド
Publication of JP2023516300A publication Critical patent/JP2023516300A/ja
Publication of JPWO2021173964A5 publication Critical patent/JPWO2021173964A5/ja
Publication of JP2023516300A5 publication Critical patent/JP2023516300A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022551637A 2020-02-28 2021-02-26 腫瘍浸潤リンパ球の活性化及び増殖のための方法 Pending JP2023516300A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062983416P 2020-02-28 2020-02-28
US62/983,416 2020-02-28
US202063074841P 2020-09-04 2020-09-04
US63/074,841 2020-09-04
US202163144853P 2021-02-02 2021-02-02
US63/144,853 2021-02-02
PCT/US2021/019861 WO2021173964A1 (en) 2020-02-28 2021-02-26 Methods for activation and expansion of tumor infiltrating lymphocytes

Publications (3)

Publication Number Publication Date
JP2023516300A true JP2023516300A (ja) 2023-04-19
JPWO2021173964A5 JPWO2021173964A5 (https=) 2024-01-26
JP2023516300A5 JP2023516300A5 (https=) 2024-01-26

Family

ID=77491997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551637A Pending JP2023516300A (ja) 2020-02-28 2021-02-26 腫瘍浸潤リンパ球の活性化及び増殖のための方法

Country Status (8)

Country Link
US (1) US20230108584A1 (https=)
EP (1) EP4110352A4 (https=)
JP (1) JP2023516300A (https=)
KR (1) KR20230034198A (https=)
CN (1) CN116096865A (https=)
AU (1) AU2021228701A1 (https=)
CA (1) CA3168932A1 (https=)
WO (1) WO2021173964A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109536444B (zh) * 2018-12-11 2022-06-28 吉林省拓华生物科技有限公司 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
CN114901805B (zh) 2020-11-19 2023-07-25 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的培养方法及其用途
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
US20240197873A1 (en) * 2021-04-23 2024-06-20 Suzhou Grit Biotechnology Co., Ltd. Modified tumor-infiltrating lymphocyte and use thereof
AU2022409848A1 (en) * 2021-12-17 2024-07-04 Instil Bio, Inc. Processing of tumor infiltrating lymphocytes
CN118414422A (zh) * 2021-12-30 2024-07-30 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
EP4471128A4 (en) * 2022-01-29 2026-03-04 Suzhou Grit Biotechnology Co Ltd Modified tumor infiltrating lymphocyte and use thereof
WO2024020531A1 (en) * 2022-07-21 2024-01-25 Tract Therapeutics, Inc. Immune cell expansion and uses thereof
WO2024215414A1 (en) * 2023-04-12 2024-10-17 Beam Therapeutics Inc. Modified immune effector cells with improved efficacy
CN117417894A (zh) * 2023-09-15 2024-01-19 毕诺济(上海)生物技术有限公司 敲除Roquin-1和/或Regnase-1基因的肿瘤浸润淋巴细胞及其应用
WO2025092690A1 (zh) * 2023-10-30 2025-05-08 苏州沙砾生物科技有限公司 一种修饰的细胞及其用途
WO2025096638A2 (en) * 2023-10-30 2025-05-08 Turnstone Biologics Corp. Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
WO2025106513A1 (en) * 2023-11-13 2025-05-22 KSQ Therapeutics, Inc. Methods for producing edited tumor infiltrating lymphocytes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019100023A1 (en) * 2017-11-17 2019-05-23 Iovance Biotherapeutics, Inc. Til expansion from fine needle aspirates and small biopsies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2711418B1 (en) * 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
RU2671897C2 (ru) * 2013-03-01 2018-11-07 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
WO2015157636A1 (en) * 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
JP7057748B2 (ja) * 2015-07-16 2022-04-20 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 遺伝子改変された抗第三者中枢性メモリーｔ細胞および免疫療法におけるその使用
EP3364969A4 (en) * 2015-10-20 2019-07-10 Kite Pharma, Inc. METHOD FOR THE PRODUCTION OF T CELLS FOR T CELL THERAPY
BR112019013940A2 (pt) * 2017-01-06 2020-02-11 Iovance Biotherapeutics, Inc. Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica.
US20200224161A1 (en) * 2017-05-10 2020-07-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US20190284553A1 (en) * 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019100023A1 (en) * 2017-11-17 2019-05-23 Iovance Biotherapeutics, Inc. Til expansion from fine needle aspirates and small biopsies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Q.YE, ET AL., HUMAN CANCER BIOLOGY, vol. Vol.20(1), JPN6025002646, 2014, pages 44 - 55, ISSN: 0005762858 *
V.BALDAN, ET AL., BRITISH JOURNAL OF CANCER, vol. 112, no. 9, JPN6025002645, 2015, pages 1510 - 1518, ISSN: 0005762859 *
Z.LIU, ET AL., ONCOIMMUNOLOGY, vol. Vol.6, No.2, e1252894, JPN6025002644, 2017, pages 1 - 9, ISSN: 0005762857 *

Also Published As

Publication number Publication date
EP4110352A4 (en) 2024-04-24
KR20230034198A (ko) 2023-03-09
CN116096865A (zh) 2023-05-09
WO2021173964A1 (en) 2021-09-02
US20230108584A1 (en) 2023-04-06
AU2021228701A1 (en) 2022-09-15
CA3168932A1 (en) 2021-09-02
EP4110352A1 (en) 2023-01-04

Similar Documents

Publication Publication Date Title
JP2023516300A (ja) 腫瘍浸潤リンパ球の活性化及び増殖のための方法
JP7847385B2 (ja) 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
JP7781761B2 (ja) キメラ抗原受容体発現細胞を作製する方法
AU2019331496B2 (en) Methods of making chimeric antigen receptor-expressing cells
JP2025159098A (ja) 腫瘍浸潤リンパ球の活性化及び増殖方法
AU2026200217A1 (en) Compositions and methods for immunooncology
TW202134264A (zh) 嵌合抗原受體及其用途
JP2024081796A (ja) 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
TW202241508A (zh) 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
JP2023516008A (ja) キメラ抗原受容体発現細胞を作製する方法
KR20200133218A (ko) 개선된 면역요법을 위한 유전자-조절 조성물 및 방법
JP2021518161A6 (ja) 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
KR20200130826A (ko) 개선된 면역요법을 위한 유전자-조절 조성물 및 방법
WO2020057666A1 (zh) 表达有嵌合受体的t细胞
TW202346573A (zh) 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
EP3377086B1 (en) Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
KR20240090127A (ko) 개선된 면역치료법을 위한 방법 및 조성물
RU2822196C2 (ru) Способы получения клеток, экспрессирующих химерный антигенный рецептор
WO2024077174A1 (en) Methods for culturing nr4a-deficient cells
JP2022512915A (ja) 改良された腫瘍反応性ｔ細胞の選択
HK1254123A1 (en) Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
HK1254123B (en) Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260323